Ekso Bionics

Company Overview

June 2014

Proprietary | 2

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Current Report on Form 8-K filed on March 31, 2014. The Company does not undertake to update these forward-looking statements.

FORWARD LOOKING STATEMENTS

Proprietary | 3

Lisa Hughes

FIRST, SOME INTRODUCTIONS

Jason Gieser

Proprietary | 4

INTRODUCTION TO EKSO BIONICS

Ekso Bionics designs and develops wearable robotic

exoskeletons to augment human strength, endurance,

and mobility

• We are in the midst of one of the greatest technological

revolutions in history

• We are committed to applying the latest technology and

engineering to help people rethink current physical limitations and

achieve the remarkable.

• We are executing a synergistic dual business strategy

o Technology and IP developer through leading R&D and

engineering capability;

o Designer, manufacturer and distributor of advanced

wearable robotic exoskeletons

EKSO LABS

EKSO

LABS

Expands

Exoskeleton

Functionality Lockheed

Martin

• HULC

• Mantis

DARPA

An

Original

Idea With

The Future

In Mind

National

Science

Foundation

EKSO™

HULC MANTIS TALOS

US Special

Operations

Command

• TALOS

Continually

Integrating

Emerging

Technologies

We Developed Our Own Exoskeleton Laboratory

EXOHIKER

Healthcare

Products

“EKSO”

“GT”

EKSO GT™

Proprietary | 5

Proprietary and Confidential | 6

MULTIPLE LARGE MARKET APPLICATIONS

Current Market Additional Market Applications

Healthcare Rehab Healthcare Home Military Industrial Consumer

Medical Military Industrial Consumer

Applications

• Spinal Cord Injury

(“SCI”)

• Stroke

• Traumatic Brain Injury

• Early Mobilization

• Cerebral Palsy

• At Home Rehab

• Gait Training

• Wellness

• Added mobility

option

• Ground Soldiers

• Depots

Manufacturing

• Logistics

• Construction

• First Response

• Manufacturing

• Moving

• Elderly

• Outdoor Sports

• Extreme Athletics

Customers

• Neuro-Rehab Centers

US and Europe

• Distributors

• Individuals

• At Home HC

Providers

• Lockheed Martin

• DARPA

• US SOCOM

• Lockheed Martin

• Retail

TALOS - NEXT GENERATION EXOSKELETONS

US Special Operations Command (USSOCOM)

o TALOS – R&D project led by Admiral McRaven to develop the Iron Man suit

o Ekso Bionics first company globally to be awarded a contract under this program,

direct with USSOCOM

o Developing technologies that will apply to many able bodied applications

o Ekso Bionics-developed IP to remain with Ekso Bionics

Proprietary | 7

Healthcare Rehabilitation Market

"The Ekso suit has given me a chance to do something that I

never thought I would ever do again. I can walk and look

people in the eye. I can hug people.” Tamara Mena, Ekso

Ambassador

Proprietary | 8

Proprietary | 9

• 800,000 Stroke Cases Each Year (2)

• Most will Have Some Level of Hemiplegia

• Ekso can address ~25% of stroke survivors (3)

HEALTHCARE REHAB MARKET OVERVIEW

STROKE SPINAL CORD INJURY

•14,000 Spinal Cord Injuries Each Year in US (4)

• Potential Ekso Patients Include:

•All complete and incomplete paraplegics

•All incomplete tetraplegics

• Ekso can serve as a tool to prevent re-hospitalization

(2) (3) (Source) The Christopher and Dana Reeves Foundation

(Source) Wintergreen Research (1)

(4)

ROBOTIC REHAB TO GROW 181% PER YEAR (1) 5.6 M IN US LIVE WITH PARALYSIS

51 64 112 256

663

1,240

1,882

0

500

1,000

1,500

2,000

2014 2015 2016 2017 2018 2019 2020

In U

S$000,0

00

Rehab Robot Market Forecast, Worldwide

Proprietary | 10

GROWING WORLDWIDE REHAB PRESENCE

NORTH AMERICA EUROPE

60 centers as of Q1, 2014 in US, Europe, Canada, Mexico,

and South Africa

Proprietary | 11

HOW THIS EXPANSION WILL CONTINUE

• Clinical Efficacy – an expanding group of KOLs are

sharing preliminary data

• Beating expectations for exoskeletons

• PLEASE – Check our references!

• Reimbursement – believe it or not – is not important now,

will be when we eventually go into homes.

• Adoption – Growing number of multi-Ekso customers.

• Return on Investment – Multiple ways our customers are

seeing Ekso pay for itself

Proprietary | 12

PROSPECTIVE BENEFITS AND ROI

Benefits Facts, Figures and Anecdotes

Attracts additional

patients

“[The Ekso] attracted 12 new SCI inpatients

to our facility”

Reduces length of Stay Patients are 86% more likely to go home if

able to walk

Increase bed turnover

Mitigates providers’ exposure to capitation

of reimbursement not solely tied to length of

stay

Reduces readmissions “Few stroke patients survive for 5 years

without a hospital readmission”

Reduces medical costs

“reported reduction in habitual

musculoskeletal pain, and lessening of

lower extremity muscle spasms.”

Prevents injuries to

physical therapists

Patient repositioning is a major cause of

work-related injuries and missed time for

PTs.

Leads to additional rehab

hours

“It was phenomenal…walking on my own

two feet, walking naturally”

Prospective Benefits Facts, Figures and Anecdotes

Improve overall health Improves both psychological and

physical health

Reduce hospital readmissions

Prevents UTIs, pneumonia, pressure

ulcers and many other complications

(~$10K annually)

Require fewer checkups Upholds better overall health saving

money on checkups (~$3K annually)

Save money on prescriptions “I no longer need spasticity

medications” (~$4K annually)

Fewer rehab sessions “I will be able to do rehab in my own

home” (~$4K annually)

Less home remodeling Individuals will eventually have much

more mobility around their homes

Reduce Social Costs 90% of SCI patients do not return to

work

REHAB MARKET: PROVIDERS

Cost Savings and Revenue Generation

HOME MARKET: PAYERS AND PATIENTS

Cost Savings and Health Improvement

Proprietary | 13

30 Unique U.S. Patents

o Status

• 7 issued

• 11 in prosecution

• 12 provisional

o Ownership

• 6 exclusively licensed from UCB

• 7 co-owned with UCB

• 17 held by Ekso Bionics

95 International Applications

IP – ACROSS ALL OF OUR MARKETS

Military Medical Commercial

Industrial

We have aggressively pursued IP for Medical, Military, and Commercial applications

Subject matter ranges from novel customer features to advanced control systems

By making full use of the international patent treaties, we have broad coverage overseas

RUC006

RUC006C

RUC003

BBI006

BBI004

EKS010

EKSO07

RUC007

BBI005

BBI005CIP

BBI009

BBI010

EKS002

BB1004C

EKSO04

RUC004

RUC005

BBI003

BBI002

BBI007

BBI008

EKSO03

EKSO05

EKSO06

EKSO08

EKSO09

EKSO12

EKSO13

EKSO14

EKSO15

Let’s Walk

Proprietary | 14

Proprietary | 15

Complete PP and APO to enable business plan through mid-2015.

Hire Senior Sales and Marketing Executives

• Tom Looby, Chief Marketing Officer

• Glenn Davis, VP North America Sales

Secure Two New Ekso Lab Projects

TALOS Secured

Grow IP through additional non-dilutive funding

Expand Licensing Partnerships

Cross over 10 million steps for Ekso medical devices

2014-2015 MILESTONES

Proprietary | 16

• As of March 2014, ~$80 million has been invested in Ekso’s Technology

• Of that, ~$35 million has been non-dilutive:

o ~$27 million has been in the form of grants from DARPA, NSF, NIST and others

o ~$7 million as non-recurring engineering services from Lockheed and the US Government

o $1 million in license payments

• ~$45 million in equity invested to date

• Our APO

o First closing January 15, 2014; final closing February 6

o 30.3 million units - $1.00 share plus a $2.00 five-year warrant

o After repayment of debt and fees, netted ~$19 million.

o 78.4 million actual shares outstanding

o 129.5 million fully diluted

INSTITUTIONAL INVESTORS RECENTLY ENTERING

20.3%

19.5%

16.9%

43.3%

Summary Cap Table, Post APO

Founders andEmployees

Institutions

ChickasawNation/Lockheed

Individuals/Other

Proprietary | 17

Thank You

“Walking in the Ekso means that I was able to keep a promise

to my family that I would walk again after my accident.”

Chris Tagatac, Ekso Ambassador